Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) EVP Sells 51,504 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) EVP Andrew Polovin sold 51,504 shares of the firm's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total value of $2,183,254.56. Following the completion of the transaction, the executive vice president now owns 246,085 shares of the company's stock, valued at $10,431,543.15. This trade represents a 17.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Tempus AI Stock Down 2.4 %

Shares of NASDAQ TEM traded down $0.99 during trading on Friday, hitting $41.00. The company had a trading volume of 5,041,241 shares, compared to its average volume of 1,427,998. The firm's fifty day simple moving average is $52.88. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49.

Analyst Upgrades and Downgrades

TEM has been the topic of a number of recent research reports. Bank of America upped their target price on Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a research report on Friday. Wolfe Research initiated coverage on shares of Tempus AI in a research note on Friday. They issued an "outperform" rating and a $60.00 price objective on the stock. Stifel Nicolaus downgraded shares of Tempus AI from a "buy" rating to a "hold" rating and boosted their target price for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Piper Sandler reaffirmed a "neutral" rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, Loop Capital boosted their price objective on Tempus AI from $48.00 to $57.00 and gave the company a "buy" rating in a report on Tuesday, October 15th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $56.00.

Institutional Investors Weigh In On Tempus AI

Several institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. grew its holdings in shares of Tempus AI by 1.0% during the third quarter. Franklin Resources Inc. now owns 811,311 shares of the company's stock worth $45,920,000 after buying an additional 8,387 shares in the last quarter. Tidal Investments LLC acquired a new position in Tempus AI during the third quarter worth about $7,633,000. Teachers Retirement System of The State of Kentucky grew its stake in Tempus AI by 6.3% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 126,500 shares of the company's stock valued at $7,160,000 after acquiring an additional 7,500 shares in the last quarter. Geode Capital Management LLC raised its holdings in Tempus AI by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company's stock valued at $7,537,000 after acquiring an additional 539 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in Tempus AI in the 3rd quarter worth approximately $502,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.